A Novo spokesperson said in a statement to Reuters that the new analysis "demonstrates for the first time the benefits of semaglutide 2.4 mg in improving kidney function in people with cardiovascular disease and overweight or obesity, without diabetes, a high-risk population with increased need for kidney protection
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/NwljrdI
via gqrds
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment